Navigation Links
QUANTUM GENOMICS Is Making Significant Advances in the Development of a New, Groundbreaking Drug to Help with Treatment-resistant Chronic Hypertension
Date:8/16/2019

Quantum Genomics are the creators of Firibastat, a first-in-class brain aminopeptidase inhibitor (BAPAI) that could potentially treat treatment-resistant hypertension by acting in the brain to interfere with the renin-angiotensin system.

It is estimated that there are around 150 million people worldwide that are affected by treatment-resistant hypertension, resulting in almost 10 million deaths per year from complications due to high blood pressure. With such a high number of people dealing with this chronic condition (around 1.1 billion people). For those with treatment resistant hypertension, they can be more susceptible to complications associated with hypertension such as heart failure, coronary artery disease, stroke, kidney disease and peripheral artery disease.

Standard treatments for hypertension include extensive lifestyle changes to address potential factors that may have contributed to the disease and multi-drug regimens, based on preference of the treating doctor.

Firibastat works by crossing the blood-brain barrier and modulating the brain renin-angiotensin system (RAS). RAS is a hormone system that controls blood pressure in part by modulating dilation and constriction of the blood vessels throughout the body, there is a RAS system in the brain, and at the peripheral level (kidney, heart…). By modulating the brain RAS, Firibastat decreases vasopressin release, decreases sympathetic nerve activity and improves baroreflex. These effects lead to a vasodilatation and an increased diuresis, thereby decreasing blood pressure.

In the brain, Firibastat causes the inhibition of aminopeptidase A (APA) which is a key enzyme in the RAS. By inhibiting APA, Firibastat decreases levels of angiotensin III in the brain, a key protein that drives vasoconstriction. It is because of these actions that take place in the brain due to Firibastat that the drug could potentially address hypertension in the population of patients that have been resistant to current treatments of hypertension that act at the peripheral level.

Quantum Genomics has concluded NEW-HOPE, which is phase 2b trial in difficult-to-treat hypertension. The trial included 256 overweight and obese patients with primary hypertension across the US including 53% of minorities patients (of whom 38% of African-American) , 44% are female, and 26% are above the age of 65 years old. This kind of population is more likely to suffer from resistant hypertension

Indeed treatment-resistant hypertension is not equally common across all demographics and ethnicities and was more prevalent in black, Hispanic, elderly and female populations. Obese patients with hypertension were 5 times more likely to be resistant to treatment.
Results of the trial indicated that treatment with Firibastat for 8 weeks resulted in significant (p<0.0001) decreased office systolic blood pressure by 9.5 mmHg (from 153.9 down to 144.4 mmHg) and was determined to be safe. Firibastat’s efficiency was similar in black (-10.5mmHg) and non-black (-8.9mmHg) populations, contrary to other anti-hypertensive classes

The trial also showed a larger blood pressure decrease for patients with higher baseline hypertension, a predictive factor of resistant hypertension. Based on the outcome of the NEW-HOPE trial, Quantum Genomics will initiate a phase 3 pivotal trial in resistant hypertension with Firibastat.

Based in Paris and New York, Quantum Genomics trades on the OTCQXt in the United States and Euronext Paris.

For more information, please visit http://www.quantum-genomics.com ,or follow us on Twitter and LinkedIn.

Media Contact:
NAME – Jean-Philippe MILON
EMAIL – jean-philippe.milon@quantum-genomics.com

Read the full story at https://www.prweb.com/releases/quantum_genomics_is_making_significant_advances_in_the_development_of_a_new_groundbreaking_drug_to_help_with_treatment_resistant_chronic_hypertension/prweb16508291.htm.


'/>"/>
Source: PRWeb
Copyright©2019 Vocus, Inc.
All rights reserved


Related medicine technology :

1. Edison Issues Update on Quantum Genomics (ALQGC)
2. Novanta Increases Ownership in Laser Quantum to over 75 Percent
3. Quantum Radiologys Mobile Breast Center Has Rolled into Atlanta
4. Cannabinoid Drug Advancements Take Off After Quantum Shift in U.S. Drug Policy
5. Quantum Plastics Acquires Transfer Solutions Wheelchair Stabilizing Devices
6. Quantum Dot Market by Product , Material, Application, and Geography- Forecast up to 2020
7. Global Quantum Dot (Display, Medical Devices, Batteries, Solar Cells, Sensors, and Others) Market 2015-2020 with QD Vision, Nanosys & Nanoco Group Dominating
8. Quantum Rehab Supports The ALS Association as Premier-Level National Partner to Provide Support for People Affected by ALS
9. Quantum Materials Begins Shipping Cadmium-Free Red and Green Quantum Dots
10. Quantum Materials CEO Stephen Squires to Speak at Rice Center for Quantum Materials Launch
11. Quantum Materials Corp to Quadruple Lab Space and Add Scientists
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/17/2019)... ... September 17, 2019 , ... Called Muss-Bits (Musical Sensory Substitution Bits) ... by Design Awards Students category. , It was developed by Associate Professor Suranga Nanayakkara ... Muss-Bits is comprised of two parts. A “sensor bit” that can be placed on ...
(Date:9/17/2019)... ... 17, 2019 , ... Drs. Mario J. Canal and Ben ... patients from Cherry Hill, NJ for tooth extractions, with or without a referral. ... removal is necessary, they use advanced equipment and techniques, as well as proper ...
(Date:9/17/2019)... ... September 17, 2019 , ... ... experience revolutionary Wilckodontics® treatment . An alternative to conventional orthodontics, the Wilckodontics ... that surrounds each tooth. , Conventional orthodontics uses brackets and wires that apply ...
Breaking Medicine Technology:
(Date:9/17/2019)... ... 17, 2019 , ... Encouraging a spirit of partnership and ... President of Insurance Plan Management for Dental Care Alliance, the 2019 Don Mayes ... their annual conference, CONVERGE 2019, in Orlando. This award commends exemplary service by ...
(Date:9/17/2019)... ... September 17, 2019 , ... Dr. Jacqueline Subka ... laser dentistry . A minimally invasive approach to gum surgery, laser dentistry is ... Laser dentistry is gentle and effective because it simply uses laser light to ...
(Date:9/17/2019)... ... 17, 2019 , ... What if a drug that sits ... patients? In companion presentations at the American Society for Therapeutic Radiation Oncology (ASTRO) ... evidence that low-dose aspirin and other anti-inflammatories may improve survival in patients undergoing ...
(Date:9/17/2019)... British Columbia (PRWEB) , ... September 17, 2019 ... ... (STC) announce the availability of the newly updated International Audit Protocol Consortium (IAPC) ... IAPC EHS audit protocols to understand the scope of their EHS regulatory obligations ...
(Date:9/17/2019)... ... September 17, 2019 , ... ... of services, welcomes Dr. Yevgeniya (Jenny) Gartshteyn to their team of expert physicians. ... she previously held the Clinical Appointment of Assistant Professor in Medicine for the ...
Breaking Medicine News(10 mins):